Stocks and Investing Stocks and Investing
Tue, February 21, 2017
Mon, February 20, 2017

FTC, M, REZ, FIW, AVEO, IGF Are Seasonally Ripe To Go Up In the Next Five Weeks


Published on 2017-02-20 01:45:33 - WOPRAI
  Print publication without navigation


February 20, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring the Seasonality of FstTr ET AlDex Shs Large Cap Growth AlphaDEX Fund (NASDAQ:FTC), Macy's Inc. (NYSE:M), iShares FTSE NAREIT Residential Index Fund (NYSE:REZ), First Trust ISE Water Index Fund (NYSE:FIW), AVEO Pharmaceuticals Inc. (NASDAQ:AVEO), iShs Glb Infr Shs (NASDAQ:IGF) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. buyins.net is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

The following stocks are expected to go Up:

  Symbol  Company                          Expected Return  Odds                 By The Following Date
  FTC     FstTr ET AlDex Shs Large Cap Growth AlphaDEX Fund  4.25%            88.89% (8 of 9)      Friday, March 31st 2017
  M       Macy's Inc.                      8.79%            84.00% (21 of 25)    Friday, March 17th 2017
  REZ     iShares FTSE NAREIT Residential Index Fund  5.75%            100.00% (9 of 9)     Monday, April 3rd 2017
  FIW     First Trust ISE Water Index Fund  5.13%            88.89% (8 of 9)      Monday, April 3rd 2017
  AVEO    AVEO Pharmaceuticals Inc.        2.45%            66.67% (4 of 6)      Friday, February 24th 2017
  IGF     iShs Glb Infr Shs                3.24%            100.00% (9 of 9)     Monday, April 3rd 2017
FstTr ET AlDex Shs Large Cap Growth AlphaDEX Fund (NASDAQ:FTC) - The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the Nasdaq AlphaDEX Large Cap Growth Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is designed to select growth stocks from the NASDAQ US 500 Large Cap Index (the "base index") that may generate positive alpha, or risk-adjusted returns, relative to traditional indices through the use of the AlphaDEX selection methodology..

Macy's Inc. (NYSE:M) - Macy s, Inc., together with its subsidiaries, operates stores, Websites, and mobile applications. Its stores and Websites sell a range of merchandise, including apparel and accessories for men, women, and children; cosmetics; home furnishings; and other consumer goods. The company also operates stores that offer a range of women's, men's, and children's apparel; shoes; fashion accessories; housewares; home textiles; intimate apparel; and jewelry. As of January 4, 2017, it operated approximately 880 stores in the United States, the District of Columbia, Guam, and Puerto Rico under the Macy s, Bloomingdale s, Bloomingdale s Outlet, Macy s Backstage, and Bluemercury brands, as well as Websites, including macys.com, bloomingdales.com, and bluemercury.com. In addition, it operates as a beauty products and spa retailer. The company was formerly known as Federated Department Stores, Inc. and changed its name to Macy s, Inc. in June 2007. Macy s, Inc. was founded in 1830 and is based in Cincinnati, Ohio..

iShares FTSE NAREIT Residential Index Fund (NYSE:REZ) - iShares Trust.

First Trust ISE Water Index Fund (NYSE:FIW) - First Trust ExchangeTraded Fund.

AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) - AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The company s pipeline of product candidates include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors for renal cell carcinoma and other cancers; Ficlatuzumab, an anti-hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer, including chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincent s Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts..

iShs Glb Infr Shs (NASDAQ:IGF) - The investment seeks to track the S&P Global Infrastructure IndexTM. The fund generally invests at least 90% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities and may invest up to 10% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is designed to track performance of the stocks of large infrastructure companies in developed or emerging markets that must be domiciled in developed markets, or whose stocks are listed on developed market exchanges around the world..

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net


Contributing Sources